cobimetinib dose to 20 mg. After discontinuation of a moderate CYP3A inhibitor, resume cobimetinib 60 mg. Use an alternative to a moderate CYP3A inhibitor in patients who are taking a reduced dose of cobimetinib (40 or 20 mg daily).crizotinibcrizotinib and sertraline both increase QTc interval. Avoid or Use Alternate Drug.cyclobenzaprinesertraline and cyclobenzaprine both increase serotonin levels. Avoid or Use Alternate Drug.dacomitinibdacomitinib will increase the level or effect of sertraline by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid use with CYP2D6 substrates where minimal increases in concentration of the CYP2D6 substrate may lead to serious or life-threatening toxicities. desfluranedesflurane and sertraline both increase QTc interval. Avoid or Use Alternate Drug.desipraminesertraline and desipramine both increase serotonin levels. Avoid or Use Alternate Drug.desipramine and sertraline both increase QTc interval. Avoid or Use Alternate Drug.desvenlafaxinesertraline and desvenlafaxine both increase serotonin levels. Avoid or Use Alternate Drug.dextromethorphansertraline and dextromethorphan both increase serotonin levels. Avoid or Use Alternate Drug.disopyramidesertraline and disopyramide both increase QTc interval. Avoid or Use Alternate Drug.dofetilidedofetilide increases toxicity of sertraline by QTc interval. Avoid or Use Alternate Drug.dolasetrondolasetron, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.dosulepinsertraline and dosulepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepinsertraline and doxepin both increase serotonin levels. Avoid or Use Alternate Drug.doxepin and sertraline both increase QTc interval. Avoid or Use Alternate Drug.droperidolsertraline and droperidol both increase QTc interval. Avoid or Use Alternate Drug.duloxetinesertraline will increase the level or effect of duloxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.duloxetine and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.elacestrantsertraline will increase the level or effect of elacestrant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.eliglustatsertraline increases levels of eliglustat by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Moderate CYP3A4 inhibitors are not recommended with eliglustat poor or intermediate metabolizers; reduce eliglustat dose from 84 mg BID to 84 mg once daily in extensive metabolizers .encorafenibencorafenib and sertraline both increase QTc interval. Avoid or Use Alternate Drug.entrectinibsertraline will increase the level or effect of entrectinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of moderate CYP3A4 inhibitors with entrectinib, a CYP3A4 substrate. If coadministration unavoidable, reduce dose to 200 mg/day for patients aged 12 y or older with BSA >1.50m2. Resume previous entrectinib dose after discontinuing moderate CYP3A inhibitor for 3-5 elimination half-lives.entrectinib and sertraline both increase QTc interval. Avoid or Use Alternate Drug.eribulineribulin and sertraline both increase QTc interval. Avoid or Use Alternate Drug.erythromycin basesertraline and erythromycin base both increase QTc interval. Avoid or Use Alternate Drug.erythromycin ethylsuccinatesertraline and erythromycin ethylsuccinate both increase QTc interval. Avoid or Use Alternate Drug.erythromycin stearatesertraline and erythromycin stearate both increase QTc interval. Avoid or Use Alternate Drug.escitalopramescitalopram and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.escitalopram increases toxicity of sertraline by QTc interval. Avoid or Use Alternate Drug.fedratinibsertraline will increase the level or effect of fedratinib by Other (see comment). Avoid or Use Alternate Drug. Avoid coadministration of fedratinib (a CYP3A4 and CYP2C19 substrate) with dual CYP3A4 and CYP2C19 inhibitor. Effect of coadministration of a dual CYP3A4 and CYP2C19 inhibitor with fedratinib has not been studied.fentanylsertraline will increase the level or effect of fentanyl by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl intranasalsertraline will increase the level or effect of fentanyl intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl intranasal, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transdermalsertraline will increase the level or effect of fentanyl transdermal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl transdermal, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fentanyl transmucosalsertraline will increase the level or effect of fentanyl transmucosal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration of CYP3A4 inhibitors with fentanyl is necessary, monitor patients for respiratory depression and sedation at frequent intervals and consider fentanyl dose adjustments until stable drug effects are achieved.fentanyl transmucosal, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.fexinidazolefexinidazole and sertraline both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of fexinidazole with drugs known to block potassium channels or prolong QT interval.flecainidesertraline and flecainide both increase QTc interval. Avoid or Use Alternate Drug.fluoxetinesertraline will increase the level or effect of fluoxetine by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug.fluoxetine and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.fluvoxaminefluvoxamine and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.sertraline and fluvoxamine both increase QTc interval. Avoid or Use Alternate Drug.foscarnetsertraline and foscarnet both increase QTc interval. Avoid or Use Alternate Drug.gilteritinibgilteritinib will decrease the level or effect of sertraline by Other (see comment). Avoid or Use Alternate Drug. Coadministration of gilteritinib with drugs that inhibit 5HT2B or sigma nonspecific receptors. Avoid use of these drugs with gilteritinib unless coadministration is necessary.givosirangivosiran will increase the level or effect of sertraline by affecting hepatic enzyme CYP2D6 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of sensitive CYP2D6 substrates with givosiran. If unavoidable, decrease the CYP2D6 substrate dosage in accordance with approved product labeling.glasdegibsertraline and glasdegib both increase QTc interval. Avoid or Use Alternate Drug.granisetrongranisetron, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.hydromorphonehydromorphone, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.hydroxychloroquine sulfatehydroxychloroquine sulfate and sertraline both increase QTc interval. Avoid or Use Alternate Drug.ibrutinibsertraline increases levels of ibrutinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration with moderate CYP3A4 inhibitors, reduce ibrutinib dose to 280 mg qDay (B-cell malignancies) or 420 mg qDay (graft versus host disease). After CYP3A inhibitor discontinuation, resume previous dose of ibrutinib.ibutilidesertraline and ibutilide both increase QTc interval. Avoid or Use Alternate Drug.iloperidonesertraline and iloperidone both increase QTc interval. Avoid or Use Alternate Drug.imipraminesertraline and imipramine both increase serotonin levels. Avoid or Use Alternate Drug.sertraline and imipramine both increase QTc interval. Avoid or Use Alternate Drug.infigratinibsertraline will increase the level or effect of infigratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.inotuzumabsertraline and inotuzumab both increase QTc interval. Avoid or Use Alternate Drug.irinotecansertraline will increase the level or effect of irinotecan by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.irinotecan liposomalsertraline will increase the level or effect of irinotecan liposomal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.isofluraneisoflurane and sertraline both increase QTc interval. Avoid or Use Alternate Drug.ivabradinesertraline will increase the level or effect of ivabradine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of ivabradine with moderate CYP3A4 inhibitors.ivosidenibivosidenib and sertraline both increase QTc interval. Avoid or Use Alternate Drug. Avoid coadministration of QTc prolonging drugs with ivosidenib or replace with alternate therapies. If coadministration of a QTc prolonging drug is unavoidable, monitor for increased risk of QTc interval prolongation.lefamulinlefamulin and sertraline both increase QTc interval. Avoid or Use Alternate Drug.lemborexantsertraline will increase the level or effect of lemborexant by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of lemborexant with moderate or strong CYP3A inhibitors.lenvatinibsertraline and lenvatinib both increase QTc interval. Avoid or Use Alternate Drug.levomilnacipranlevomilnacipran and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.linezolidlinezolid and sertraline both increase serotonin levels. Avoid or Use Alternate Drug. Linezolid may increase serotonin as a result of MAO-A inhibition. If linezolid must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last linezolid dose or after 2 weeks of monitoring, whichever comes first.lofepraminesertraline and lofepramine both increase serotonin levels. Avoid or Use Alternate Drug.lofexidinesertraline and lofexidine both increase QTc interval. Avoid or Use Alternate Drug.lopinavirsertraline and lopinavir both increase QTc interval. Avoid or Use Alternate Drug.lorcaserinsertraline and lorcaserin both increase serotonin levels. Avoid or Use Alternate Drug.lurbinectedinsertraline will increase the level or effect of lurbinectedin by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug.macimorelinmacimorelin and sertraline both increase QTc interval. Avoid or Use Alternate Drug. Macimorelin causes an increase of ~11 msec in the corrected QT interval. Avoid coadministration with drugs that prolong QT interval, which could increase risk for developing torsade de pointes-type ventricular tachycardia. Allow sufficient washout time of drugs that are known to prolong the QT interval before administering macimorelin.maprotilinesertraline and maprotiline both increase serotonin levels. Avoid or Use Alternate Drug.mefloquinemefloquine increases toxicity of sertraline by QTc interval. Avoid or Use Alternate Drug. Mefloquine may enhance the QTc prolonging effect of high risk QTc prolonging agents.meperidinesertraline and meperidine both increase serotonin levels. Avoid or Use Alternate Drug.meperidine, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.methadonesertraline and methadone both increase QTc interval. Avoid or Use Alternate Drug.methylene bluemethylene blue and sertraline both increase serotonin levels. Avoid or Use Alternate Drug. Methylene blue may increase serotonin as a result of MAO-A inhibition. If methylene blue must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity. Serotonergic therapy may be resumed 24 hours after last methylene blue dose or after 2 weeks of monitoring, whichever comes first.metoclopramidemetoclopramide and sertraline both increase serotonin levels. Avoid or Use Alternate Drug. Additive effects; increased risk for serotonin syndrome, neuroleptic malignant syndrome, dystonia, or other extrapyramidal reactionsmetoclopramide intranasalsertraline, metoclopramide intranasal. Either increases effects of the other by Other (see comment). Avoid or Use Alternate Drug. Comment: Avoid use of metoclopramide intranasal or interacting drug, depending on importance of drug to patient.midazolam intranasalsertraline will increase the level or effect of midazolam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Coadministration of moderate CYP3A4 inhibitors with midazolam intranasal causes higher midazolam systemic exposure, which may prolong sedation.midostaurinsertraline and midostaurin both increase QTc interval. Avoid or Use Alternate Drug.milnacipranmilnacipran and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.mobocertinibsertraline will increase the level or effect of mobocertinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If use of moderate CYP3A4 inhibitor unavoidable, reduce mobocertinib dose by ~50% (eg, 160 to 80 mg); closely monitor QTc interval.mobocertinib and sertraline both increase QTc interval. Avoid or Use Alternate Drug. If coadministration unavoidable, reduce mobocertinib dose and monitor QTc interval more frequently.morphinemorphine, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.moxifloxacinsertraline and moxifloxacin both increase QTc interval. Avoid or Use Alternate Drug.naloxegolsertraline will increase the level or effect of naloxegol by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministation of naloxegol with moderate CYP3A4 inhibitors is unavoidable, reduce naloxegol dose to 12.5 mg qDaynefazodonenefazodone and sertraline both increase serotonin levels. Avoid or Use Alternate Drug.neratinibsertraline will increase the level or effect of neratinib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. Avoid coadministration of neratinib with strong/moderate CYP3A4 inhibitors.netupitant/palonosetronnetupitant/palonosetron, sertraline. Either increases toxicity of the other by serotonin levels. Avoid or Use Alternate Drug.nilotinibsertraline and nilotinib both increase QTc interval. Avoid or Use Alternate Drug.nortriptylinesertraline and nortriptyline both increase serotonin levels. Avoid or Use Alternate Drug.sertraline and nortriptyline both increase QTc interval. Avoid or Use Alternate Drug.olaparibsertraline will increase the level or effect of olaparib by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Avoid or Use Alternate Drug. If coadministration with moderate CYP3A inhibitors cannot be avoided, reduce olaparib dose to 200 mg (capsule) or 150 mg (tablet) PO BID. Do not substitute tablets with capsules.olopatadine intranasalsertraline and olopatadine intranasal both increase sedation. Avoid or Use Alternate Drug. Coadministration increases risk of CNS depression, which can lead to additive impairment of